Vita Life Sciences Limited

ASX:VLS Stock Report

Market Cap: AU$106.6m

Vita Life Sciences Management

Management criteria checks 3/4

Vita Life Sciences' CEO is Andrew O'Keefe, appointed in Jan 2017, has a tenure of 7.92 years. total yearly compensation is A$886.73K, comprised of 49.8% salary and 50.2% bonuses, including company stock and options. directly owns 1.59% of the company’s shares, worth A$1.69M. The average tenure of the management team and the board of directors is 7.8 years and 5.1 years respectively.

Key information

Andrew O'Keefe

Chief executive officer

AU$886.7k

Total compensation

CEO salary percentage49.8%
CEO tenure7.9yrs
CEO ownership1.6%
Management average tenure7.8yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 23
Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

Aug 28
Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Mar 22
Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Mar 14
Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 28
Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Dec 20
A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

Aug 24
Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

May 14
If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Mar 18
Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Feb 17
Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Jan 20
Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

Dec 22
Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Nov 19
Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Jul 14
Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

CEO Compensation Analysis

How has Andrew O'Keefe's remuneration changed compared to Vita Life Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

AU$9m

Mar 31 2024n/an/a

AU$9m

Dec 31 2023AU$887kAU$442k

AU$9m

Sep 30 2023n/an/a

AU$8m

Jun 30 2023n/an/a

AU$7m

Mar 31 2023n/an/a

AU$7m

Dec 31 2022AU$984kAU$438k

AU$7m

Sep 30 2022n/an/a

AU$8m

Jun 30 2022n/an/a

AU$8m

Mar 31 2022n/an/a

AU$8m

Dec 31 2021AU$653kAU$442k

AU$8m

Sep 30 2021n/an/a

AU$8m

Jun 30 2021n/an/a

AU$7m

Mar 31 2021n/an/a

AU$6m

Dec 31 2020AU$510kAU$440k

AU$6m

Sep 30 2020n/an/a

AU$6m

Jun 30 2020n/an/a

AU$5m

Mar 31 2020n/an/a

AU$4m

Dec 31 2019AU$535kAU$442k

AU$3m

Sep 30 2019n/an/a

AU$2m

Jun 30 2019n/an/a

AU$2m

Mar 31 2019n/an/a

AU$2m

Dec 31 2018AU$424kAU$421k

AU$2m

Sep 30 2018n/an/a

AU$3m

Jun 30 2018n/an/a

AU$4m

Mar 31 2018n/an/a

AU$3m

Dec 31 2017AU$445kAU$408k

AU$3m

Compensation vs Market: Andrew's total compensation ($USD551.14K) is above average for companies of similar size in the Australian market ($USD288.21K).

Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.

CEO

Andrew O'Keefe

7.9yrs

Tenure

AU$886,732

Compensation

Mr. Andrew W. O'Keefe has been Managing Director and Director of Vita Life Sciences Limited since January 1, 2017. Mr. O'Keefe served as Acting Managing Director of Vita Life Sciences Limited since October...

Leadership Team

NamePositionTenureCompensationOwnership
Andrew O'Keefe
MD & Director7.9yrsAU$886.73k1.59%
A$ 1.7m
Chin Khoo
CFO & Company Secretary7.6yrsAU$365.80k0.99%
A$ 1.1m
Melissa Pereira
Group Marketing Manager7.9yrsAU$175.02k0.31%
A$ 332.5k
Shaun Rutherford
Chief Executive Officer of Australiano dataAU$521.94k0.94%
A$ 997.5k
K. Beh
Chief Executive Officer of Vita Life Sciences Malaysia & Singapore5.4yrsAU$545.55k1.08%
A$ 1.1m
June Lau
General Manager of Operations & Business Supportno datano datano data
Alexandra Ward
Technical & NPD Managerno datano datano data

7.8yrs

Average Tenure

Experienced Management: VLS's management team is seasoned and experienced (7.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Andrew O'Keefe
MD & Director7.9yrsAU$886.73k1.59%
A$ 1.7m
Henry Townsing
Non-Executive Chairman13yrsAU$136.90k0.77%
A$ 821.4k
Peter Osborne
Independent Non-Executive Director1.3yrsAU$16.67k0.045%
A$ 48.0k
Jack Teoh
Non-Executive Director2.3yrsAU$37.21kno data

5.1yrs

Average Tenure

Experienced Board: VLS's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 16:59
End of Day Share Price 2024/12/30 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vita Life Sciences Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aidan BrooksbySelect Equities Pty Ltd
Shane StoreyWilsons Advisory and Stockbroking Ltd.